Stealth Biotherapeutics Corp (MITO)

Trade MITO now with
9/23/2021 7:36:12 AM Stealth Presents Positive SBT-272 Preclinical Data; SBT-272 Shows Promise In Neurodegenerative Disease Model
8/23/2021 7:32:26 AM Stealth BioTherapeutics Announces Issuance Of U.S. Patents Covering Elamipretide For Barth Syndrome
8/5/2021 7:45:57 AM Stealth BioTherapeutics Q2 Net Loss $18.4 Mln Or $0.03/shr Vs. $12.4 Mln Or $0.02/shr Prior Year
5/18/2021 7:34:01 AM Stealth BioTherapeutics Q1 Net Loss $7.7 Mln Or $0.01/Shr Vs Loss $15.5 Mln Or $0.04/Shr Last Year
4/6/2021 7:44:21 AM Stealth BioTherapeutics FY Loss Per Share $0.10 Vs Loss $0.19 Last Year
3/16/2021 7:32:20 AM Stealth BioTherapeutics Promotes Marty Redmon To Chief Research & Development Officer
2/23/2021 7:39:39 AM Stealth Completes Enrollment Of Phase 2 Study In Dry Age-Related Macular Degeneration With Geographic Atrophy
2/10/2021 7:58:16 AM Stealth BioTherapeutics Reports Pricing Of $4.7 Mln Direct Offering Of ADS
1/5/2021 8:04:49 PM Stealth Granted Pre-NDA Meeting For Elamipretide As A Treatment For Cardiomyopathy In Barth Syndrome
8/6/2020 7:41:50 AM Stealth BioTherapeutics Q2 Net Loss $12.4 Mln Or $0.02/shr Vs. Net Loss $15.8 Mln Or $0.04/shr Last Year